The company will not receive any proceeds from the sale of the shares by the selling stockholders. Invest with Confidence: Follow TipRanks' Top ...

Vor Biopharma Inc. (NYSE:VOR – Get Free Report) has received an average rating of “Buy” from the seven analysts that are ...

Vor announced it entered into a securities purchase agreement for a private investment in public equity financing. The company expects to generate about $55.6 million in gross proceeds.

Vor Bio expects to use net proceeds from the PIPE to fund clinical and preclinical development of its pipeline candidates and for general corporate purposes. Vor Bio expects to announce updated ...

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of ...

A Buddha Air flight with 76 people on board made an emergency VOR landing at Tribhuvan International Airport in Kathmandu after experiencing a flame-out in its left engine.

Vor Bio (VOR) announced the appointment of Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio’s Board of ...

Vor Bio, a clinical-stage cell and genome engineering company, has appointed Mr. Erez Kalir to its Board of Directors, creating a new seat following a recent private investment in public equity ...

Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it has entered into a securi Preliminary data suggests improved ...

Vor Bio (NASDAQ:VOR) shares soared more than 20% in Friday pre-market trading, after it said that it has entered into a securities purchase agreement for a private investment in public equity ...